Glaxo Wellcome Ceftin
Executive Summary
Cefuroxime axetil approved Aug. 24 for the treatment of acute bacterial maxillary sinusitis in pediatric patients. The supplemental approval was based on pharmacokinetic data, post-marketing adverse event surveillance and clinical data from the condition in adults and of acute otitis media in pediatric patients